期刊
JOURNAL OF CANCER
卷 10, 期 27, 页码 6848-6857出版社
IVYSPRING INT PUBL
DOI: 10.7150/jca.36614
关键词
ADCY1; cAMP; Lung cancer; Drug resistance; Signaling pathway
类别
资金
- National High-tech R&D Program of China (863 Program) [2012AA02A517]
- National Natural Science Foundation of China [81373490, 81573508]
- Hunan Provincial Science and Technology Plan of China [2015TP1043]
- Hunan Provincial Natural Science Foundation of China [2019JJ50946]
- Youth Science Foundation of Xiangya Hospital, Central South University [2018Q014]
Adenylate cyclase 1 (ADCY1 or AC1) is a member of ADCY superfamily and was primarily found to be expressed in the brain. ADCY1 is responsible for catalyzing ATP to cyclic AMP (cAMP). As a secondary messenger, cAMP can regulate plenty of cellular activities. cAMP can perform its regulation in cellular transport through the binding to cAMP dependent protein kinases (PKAs), cAMP-activated guanine exchange factors (EPACs) and cyclic nucleotide-gated channels functioning in transduction of sensory signals (CNGs). Lung cancer is one of the leading factors of cancer-related death worldwide. Platinum-based chemotherapy is the first-line treatment for advanced lung cancer patients. In addition, surgical treatment, radiation treatment, and molecular targeted therapy are also therapeutic options for lung cancer patients in clinical settings. However, drug resistance and toxicity are the major obstacles that affect chemotherapy outcome and prognosis of lung cancer patients. And the therapeutic efficiency and adverse effects are varying with each individual. In recent years, investigations based on genetic sequencing have revealed the emerging role of ADCY1 mutations in affecting drug efficiency in various cancers such as lung cancer, esophageal cancer and colorectal cancer. The potential function of ADCY1 in chemotherapy resistance is of great importance to be noticed and investigated.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据